“Tolerogenic drugs re-establish tolerance to autoantigens ... by BHT-3021 to achieve long-term immune tolerance. These immune-modulating approaches could, in turn, be combined with ways of ...

However, considerable opportunities still exist to develop innate immune-modulating drugs, especially macrophage-targeted drugs, and this is where United Immunity could make its mark.

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review ...

In the late 1960s, researchers at the Weizmann Institute of Science, including Professors Michael Sela and Ruth Arnon and Dr.

CM-24 is under clinical development by Purple Biotech and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate ...

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for ...

Indeed, UBA1 was targeted with inhibitor drugs such as TAK-243 with some ... and elevated key immune modulators, including CXCL9, CXCL10, and MHC class I.” With a mechanism now in hand, the ...